Bankers Quit Goldman, Citigroup for Biotech Riches in Hong Kong


At least seven senior bankers and analysts from top-tier securities firms have quit to join biotechnology companies in the city since December, responding to the industry's growing demand for financial expertise after rule changes at Hong Kong's stock exchange smoothed the path for biotech initial public offerings. emerged as the latest example after people familiar with matter said last week he was to join CStone Pharmaceuticals Co.



from Biotech News